Company profile: Acerta Pharma
1.1 - Company Overview
Company description
- Provider of oncology and autoimmune drug discovery and development, including CALQUENCE (acalabrutinib) for CLL; collaborative small-molecule discovery for hematologic malignancies; innovative clinical studies; resistance biology research using multi-omic profiling; R&D on target identification and optimization; and partnering and in-licensing opportunities.
Products and services
- Drug Discovery: A covalent-binding, collaborative program with AstraZeneca that architects targeted small-molecule drugs for hematological malignancies, encompassing discovery, development, and delivery workflows
- CALQUENCE (acalabrutinib): A BTK-specific, highly selective inhibitor used to treat CLL by targeting the B-cell receptor pathway to reduce malignant B-cell survival
- Innovative Clinical Studies: A protocol-driven clinical development program exploring monotherapies and combination therapies for hematological malignancies using master protocols to accelerate therapeutic delivery.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acerta Pharma
Mustang Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for B-cell Non-Hodgkin Lymphoma, X-linked severe combined immunodeficiency (XSCID), and glioblastoma. Pipeline includes MB-106 (third-generation fully human antibody); MB-107/MB-207 (safety-modified lentiviral gene therapies for XSCID); MB-101 (IL13Rα2-targeted CAR T); MB-108 (oncolytic herpes simplex virus); and MB-109 (combining CAR T with oHSV to improve efficacy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mustang Bio company profile →
Alpheus Medical
HQ: United States
Website
- Description: Provider of a non-invasive sonodynamic therapy platform for solid body cancers that uses ultrasound to activate a cancer-targeting drug, including an SDT platform for outpatient treatment of recurrent high-grade gliomas and CV-01, an investigational drug-device using low-intensity, large-field ultrasound to target cancer cells across the brain hemisphere; CV-01 is in Phase 1 clinical trials for recurrent glioblastoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpheus Medical company profile →
Koelis
HQ: France
Website
- Description: Provider of medical imaging solutions for urologists, including KOELIS Trinity MRI/US prostate biopsy system for accurate needle guidance in prostate cancer diagnosis and treatment; OBT Fusion for prostate tracking and core location recording with precise targeting; 3D Ultrasound with motion compensation; 2nd Look Option; and transperineal and transrectal tools with 3D probes, holders, guides, and accessories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Koelis company profile →
Argos Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. Conducts clinical trial programs in cancer and HIV. Product candidates include AGS-0031 for metastatic renal cell carcinoma, AGS-0041 for HIV, and CD83.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argos Therapeutics company profile →
Dune Medical
HQ: United States
Website
- Description: Provider of intraoperative, real-time cancer detection devices using proprietary tissue characterization technology, enabling surgeons and radiologists to detect cancer in real time with potential for broad diagnostic and therapeutic applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dune Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acerta Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acerta Pharma
2.2 - Growth funds investing in similar companies to Acerta Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acerta Pharma
4.2 - Public trading comparable groups for Acerta Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →